Lexicon’s Zynquista is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2), which play a role in glucose uptake and reabsorption. Image credit: eamesBot / Shutterstock.

The US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (AdCom) has again voted against the approval of Lexicon Pharmaceutical’s Zynquista (sotagliflozin).

The AdCom voted 3-11 against Zynquista as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The committee noted that the therapy’s benefits do not outweigh its risks.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Following the latest AdCom vote, Lexicon’s stock was down by 38.7% at market open today (1 November), compared to market close on 30 October, as trading was suspended yesterday (31 October) on account of the AdCom vote.

The FDA had previously convened an AdCom to evaluate Zynquista’s efficacy in 2019. The panel voted 8-8 to decide whether the drug’s overall benefits outweighed the associated risks. The FDA ultimately declined to approve Zynquista at that time. The company provided additional data of the matched type 2 diabetes (T2D)-CKD population from the SCORED trial (NCT03315143) in the most recent AdCom, along with post hoc subgroup analysis from the three Tandem studies.

Zynquista is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2), which play a role in glucose uptake and reabsorption. In 2019, the European Medicines Agency (EMA) approved the therapy as an adjunct treatment to insulin in T1D and CKD. The therapy is also approved by the FDA to reduce the risk of cardiovascular death and heart failure in patients with either heart failure or T2D, CKD and other cardiovascular risk factors. It is marketed as Inpefa for the cardiovascular indication.

Lexicon is seeking approval for Zynquista in patients with T1D and CKD who had an estimated glomerular filtration rate (eGFR) of 45 to less than 60 or an eGFR of greater than 60 with a urine albumin-to-creatinine ratio (uACR) of 30 or greater.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While the FDA AdCom was not convinced of Zynquista’s efficacy in this population, some members did note that therapy’s benefit outweighed its risks in a subpopulation of patients who had an eGFR of 60 to less than 90 and those who have mild to moderate kidney disease. However, experts wanted more data to establish Zynquista’s efficacy in the subpopulation.

An AdCom is convened upon request of the FDA to review and evaluate the safety and efficacy data of a particular therapy. However, the AdCom recommendations are non-binding, with the final decision ultimately made by the FDA.